Post by
Breakthorough on Sep 17, 2022 4:53am
Interview
This interview with Matasar (in charge of VITALIZE trial) looks pretty optimistic. I would highlight this, because he calls VITALIZE a PIVOTAL trial: "This is a pivotal clinical trial that we have developed to attempt to better define the role for novel immunotherapy...". https://www.targetedonc.com/view/vitalize-trial-explores-maveropepimut-s-pembrolizumab-in-relapsed-refractory-dlbcl